Manuscripts and Publications

Filters: First Letter Of Last Name is K  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
K
Koss CA, Hosek SG, Bacchetti P, Anderson PL, Liu AY, Horng H, Benet LZ, Kuncze K, Louie A, Saberi P et al..  2018.  Comparison of Measures of Adherence to Human Immunodeficiency Virus Preexposure Prophylaxis Among Adolescent and Young Men Who Have Sex With Men in the United States.. Clin Infect Dis. 66(2):213-219.
Knopf AS, Ott MA, Liu N, Kapogiannis BG, Zimet GD, J Fortenberry D, Hosek SG.  2017.  Minors' and Young Adults' Experiences of the Research Consent Process in a Phase II Safety Study of Pre-exposure Prophylaxis for HIV.. J Adolesc Health. 61(6):747-754.
Knopf AS, Gilbert ALewis, Zimet GD, Kapogiannis BG, Hosek SG, J Fortenberry D, Ott MA.  2017.  Moral conflict and competing duties in the initiation of a biomedical HIV prevention trial with minor adolescents.. AJOB Empir Bioeth. 8(3):145-152.
Kiser JJ, Fletcher CV, Flynn PM, Cunningham CK, Wilson CM, Kapogiannis BG, Major-Wilson H, Viani RM, Liu NX, Muenz LR et al..  2008.  Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.. Antimicrob Agents Chemother. 52(2):631-7.
Kim-Chang JJ, Donovan K, Loop MShane, Hong S, Fischer B, Venturi G, Garvie PA, Kohn J, H Rendina J, Woods SP et al..  2019.  Higher soluble CD14 levels are associated with lower visuospatial memory performance in Youth with HIV (YWH).. AIDS.
Kim-Chang JJ, Wilson L, Chan C, Fischer B, Venturi G, Goodenow MM, Aldrovandi G, Weber TJ, Sleasman JW.  2019.  Tenofovir Has Minimal Effect on Biomarkers of Bone Health in Youth with HIV Receiving Initial Antiretroviral Therapy.. AIDS Res Hum Retroviruses. 35(8):746-754.
Kennard B, Brown L, Hawkins L, Risi A, Radcliffe J, Emslie G, Mayes T, King J, Foxwell A, Buyukdura J et al..  2014.  Development and Implementation of Health and Wellness CBT for Individuals with Depression and HIV.. Cogn Behav Pract. 21(2):237-246.
Kapogiannis BG, Leister E, Siberry GK, Van Dyke RB, Rudy B, Flynn P, Williams PL.  2016.  Prevalence of and progression to abnormal noninvasive markers of liver disease (aspartate aminotransferase-to-platelet ratio index and Fibrosis-4) among US HIV-infected youth.. AIDS. 30(6):889-98.
Kahn JA, Rudy BJ, Xu J, Secord EA, Kapogiannis BG, Thornton S, Gillison ML.  2015.  Behavioral, immunologic, and virologic correlates of oral human papillomavirus infection in HIV-infected youth.. Sex Transm Dis. 42(5):246-52.
Kahn JA, Belzer M, Chi X, Lee J, Gaur AH, Mayer K, Martinez J, Futterman DC, Stier EA, Paul ME et al..  2019.  Pre-vaccination prevalence of anogenital and oral human papillomavirus in young HIV-infected men who have sex with men.. Papillomavirus Res. 7:52-61.
Kahn JA, Xu J, Zimet GD, Liu N, Gonin R, Dillard ME, Squires K.  2012.  Risk perceptions after human papillomavirus vaccination in HIV-infected adolescents and young adult women.. J Adolesc Health. 50(5):464-70.
Kahn JA, Xu J, Kapogiannis BG, Sleasman JW.  2017.  Brief Report: Antibody Responses to Quadrivalent HPV Vaccination in HIV-Infected Young Women as Measured by Total IgG and Competitive Luminex Immunoassay.. J Acquir Immune Defic Syndr. 75(2):241-245.
Kahn JA, Lee J, Belzer M, Palefsky JM.  2018.  HIV-Infected Young Men Demonstrate Appropriate Risk Perceptions and Beliefs about Safer Sexual Behaviors after Human Papillomavirus Vaccination.. AIDS Behav. 22(6):1826-1834.
Kahn JA, Rudy BJ, Xu J, Kapogiannis B, Secord E, Gillison M.  2016.  Prevalence and risk factors for oral DNA tumor viruses in HIV-infected youth.. J Med Virol. 88(11):1944-52.
Kahn JA, Xu J, Kapogiannis BG, Rudy B, Gonin R, Liu N, Wilson CM, Worrell C, Squires KE.  2013.  Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women.. Clin Infect Dis. 57(5):735-44.
Kahn JA, Burk RD, Squires KE, Kapogiannis BG, Rudy B, Xu J, Gonin R, Liu N, Worrell C, Wilson CM.  2012.  Prevalence and risk factors for HPV in HIV-positive young women receiving their first HPV vaccination.. J Acquir Immune Defic Syndr. 61(3):390-9.
Kahana SY, Fernandez MIsabel, Wilson PA, Bauermeister JA, Lee S, Wilson CM, Hightow-Weidman LB.  2015.  Rates and correlates of antiretroviral therapy use and virologic suppression among perinatally and behaviorally HIV-infected youth linked to care in the United States.. J Acquir Immune Defic Syndr. 68(2):169-77.
Kahana SY, Jenkins RA, Bruce D, Fernandez MI, Hightow-Weidman LB, Bauermeister JA.  2016.  Structural Determinants of Antiretroviral Therapy Use, HIV Care Attendance, and Viral Suppression among Adolescents and Young Adults Living with HIV.. PLoS One. 11(4):e0151106.